Opinion|Videos|October 18, 2024
Long-term NMOSD Data
Author(s)Sean Pittock, MD
Key Takeaways
- Satralizumab and inebilizumab demonstrate sustained efficacy and favorable safety profiles in NMOSD management, reducing relapse rates significantly.
- Satralizumab targets interleukin-6 receptors, while inebilizumab targets CD19, both contributing to reduced relapse rates in NMOSD patients.
Sean Pittock, MD, discusses the long-term efficacy and safety results of other FDA-approved treatments for neuromyelitis optica spectrum disorder, including satralizumab, inebilizumab, and the off-label use of rituximab.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Can you also comment on long-term efficacy and safety results with other FDA-approved treatments, including satralizumab, inebilizumab, and off-label use of rituximab?
Advertisement
Related to this article
An updated open-label extension analysis and new MRI data from the phase 3 EPIDYS trial, presented at the 2026 AANEM Annual Meeting, add to the evidence for givinostat's long-term effects on disease progression.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.
New 12-month interim data showed functional gains with BBP-418 vs placebo, consistent benefit across genotype, age, and baseline pulmonary function subgroups, and a safety profile comparable to placebo.
Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.
A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP
4
Congress Passes ACT for ALS Reauthorization, Extending Research Programs
5